Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection.
Direct-acting antiviral agents
HCV
NS5A
NS5B
Resistance-associated substitution
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
10
2020
accepted:
30
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs). NS5A and NS5B RASs can occur in patients with HCV infection naturally and before exposure to DAAs. This study aimed to evaluate naturally-occurring NS5A and NS5B RASs in Iranian patients with HCV genotype 1a (HCV-1a) and -3a infections. In this cross-sectional study, viral RNA was extracted from serum specimens. NS5A and NS5B regions were amplified using RT-PCR followed by DNA sequencing. The results of nucleotide sequences were aligned against reference sequences of HCV-1a and -3a and the amino acid substitutions were analyzed using geno2pheno [hcv] web application. Among 135 patients with hepatitis C, NS5A amino acid substitutions/RASs were identified in 26.4% and 15.9% of patients with HCV-1a and -3a infections, respectively. The identified amino acid substitutions/RASs in the NS5A region of patients with HCV-1a infection were M28T/V/I 11.1%, Q30R/H 4.2%, L31M 1.4%, and H58Y/P/C/D/Q/S/T 16.7%. Y93H substitution was not found in HCV-1a sequences. In patients with HCV-3a infection, NS5A amino acid substitutions/RASs were A30T/K 9.5%, L31F 1.6%, P58S/T/C 3.2%, Y93H 3.2%, and Y93N 3.2%. No resistance substitutions were identified in NS5B sequences from patients with HCV-1a and -3a infections. In this study, baseline amino acid substitutions/RASs were only identified in the NS5A region in Iranian patients with HCV-1a and -3a infections, and the prevalence of these amino acid substitutions/RASs were in accordance with similar studies. There were no RASs in the HCV-1a and -3a NS5B region.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs). NS5A and NS5B RASs can occur in patients with HCV infection naturally and before exposure to DAAs.
OBJECTIVES
OBJECTIVE
This study aimed to evaluate naturally-occurring NS5A and NS5B RASs in Iranian patients with HCV genotype 1a (HCV-1a) and -3a infections.
METHODS
METHODS
In this cross-sectional study, viral RNA was extracted from serum specimens. NS5A and NS5B regions were amplified using RT-PCR followed by DNA sequencing. The results of nucleotide sequences were aligned against reference sequences of HCV-1a and -3a and the amino acid substitutions were analyzed using geno2pheno [hcv] web application.
RESULTS
RESULTS
Among 135 patients with hepatitis C, NS5A amino acid substitutions/RASs were identified in 26.4% and 15.9% of patients with HCV-1a and -3a infections, respectively. The identified amino acid substitutions/RASs in the NS5A region of patients with HCV-1a infection were M28T/V/I 11.1%, Q30R/H 4.2%, L31M 1.4%, and H58Y/P/C/D/Q/S/T 16.7%. Y93H substitution was not found in HCV-1a sequences. In patients with HCV-3a infection, NS5A amino acid substitutions/RASs were A30T/K 9.5%, L31F 1.6%, P58S/T/C 3.2%, Y93H 3.2%, and Y93N 3.2%. No resistance substitutions were identified in NS5B sequences from patients with HCV-1a and -3a infections.
CONCLUSION
CONCLUSIONS
In this study, baseline amino acid substitutions/RASs were only identified in the NS5A region in Iranian patients with HCV-1a and -3a infections, and the prevalence of these amino acid substitutions/RASs were in accordance with similar studies. There were no RASs in the HCV-1a and -3a NS5B region.
Identifiants
pubmed: 33584581
doi: 10.3389/fmicb.2020.617375
pmc: PMC7876467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
617375Informations de copyright
Copyright © 2021 Rahimi, Sharafi, Bahramali, SajadianFard, Asadi, Alavian, Iranpur Mobarakeh and Moravej.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Antivir Ther. 2017;22(3):237-246
pubmed: 28008868
BMC Infect Dis. 2010 Feb 23;10:36
pubmed: 20178583
Antimicrob Agents Chemother. 2016 May 23;60(6):3786-93
pubmed: 27067341
J Hepatol. 2016 Feb;64(2):486-504
pubmed: 26409317
Sci Rep. 2018 Jan 9;8(1):150
pubmed: 29317673
J Hepatol. 2008 Oct;49(4):634-51
pubmed: 18715665
Sci Rep. 2017 Nov 22;7(1):16017
pubmed: 29167469
PLoS One. 2015 Aug 28;10(8):e0134395
pubmed: 26317755
Infect Drug Resist. 2018 Nov 08;11:2207-2210
pubmed: 30519058
J Hepatol. 2017 Aug;67(2):224-236
pubmed: 28343981
J Clin Virol. 2013 May;57(1):13-8
pubmed: 23384816
World J Gastroenterol. 2016 Oct 28;22(40):8910-8917
pubmed: 27833382
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Hepatology. 2011 Dec;54(6):1924-35
pubmed: 21809362
Drug Resist Updat. 2018 Mar;37:17-39
pubmed: 29525636
Virus Res. 2019 Jan 2;259:54-61
pubmed: 30401643
World J Gastroenterol. 2014 Mar 21;20(11):2902-12
pubmed: 24659881
Expert Opin Pharmacother. 2018 May;19(7):749-757
pubmed: 29634360
Virol J. 2015 Nov 14;12:186
pubmed: 26577836
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Hepatology. 2019 May;69(5):1861-1872
pubmed: 29425396
Hepatology. 2014 Jan;59(1):318-27
pubmed: 24115039
World J Hepatol. 2018 Sep 27;10(9):543-548
pubmed: 30310532
J Infect Dis. 2014 Mar 1;209(5):668-75
pubmed: 24154738
Viruses. 2018 Dec 21;11(1):
pubmed: 30577623
Viruses. 2014 Nov 06;6(11):4227-41
pubmed: 25384189
Front Microbiol. 2019 Mar 19;10:535
pubmed: 30941111
J Hepatol. 2018 May;68(5):895-903
pubmed: 29221887
Viruses. 2016 Mar 25;8(4):91
pubmed: 27023593
J Hepatol. 2017 May;66(5):910-918
pubmed: 28108232
J Viral Hepat. 2012 Jul;19(7):449-64
pubmed: 22676357
Liver Int. 2012 Feb;32(2):339-45
pubmed: 22142261
Gastroenterology. 2010 Feb;138(2):447-62
pubmed: 20006612
Antiviral Res. 2020 Feb;174:104694
pubmed: 31857134
World J Gastroenterol. 2017 Jul 7;23(25):4538-4547
pubmed: 28740342
Gastroenterology. 2016 Jul;151(1):70-86
pubmed: 27080301
Therap Adv Gastroenterol. 2014 May;7(3):131-40
pubmed: 24790644
J Clin Microbiol. 2007 Apr;45(4):1102-12
pubmed: 17287328
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Gastroenterology. 2016 Sep;151(3):501-512.e1
pubmed: 27296509
Hepatol Commun. 2017 Jun 22;1(6):538-549
pubmed: 29404477
Gastroenterology. 2018 Mar;154(4):976-988.e4
pubmed: 29146520
Viruses. 2017 Aug 07;9(8):
pubmed: 28783119
J Med Chem. 2010 Oct 14;53(19):7202-18
pubmed: 20845908
Antimicrob Agents Chemother. 2013 May;57(5):2054-65
pubmed: 23403428
Virol J. 2013 Dec 17;10:355
pubmed: 24341898
Lancet. 2014 Feb 8;383(9916):515-23
pubmed: 24209977
Virol J. 2018 Sep 18;15(1):144
pubmed: 30227876
Hepat Mon. 2014 Dec 24;14(12):e22915
pubmed: 25685164
PLoS One. 2016 May 19;11(5):e0155869
pubmed: 27196673
J Med Virol. 2018 Jun;90(6):1094-1098
pubmed: 29427437
N Engl J Med. 2014 Jan 16;370(3):211-21
pubmed: 24428467
Hepatology. 2009 Feb;49(2):364-77
pubmed: 19148942
BMC Infect Dis. 2017 Nov 13;17(1):716
pubmed: 29132303
Viruses. 2018 Apr 26;10(5):
pubmed: 29701642
Int J Infect Dis. 2020 Jun;95:84-89
pubmed: 32302766
Top Antivir Med. 2017 Jul/Aug;25(3):103-109
pubmed: 28820725
Germs. 2017 Mar 1;7(1):40-44
pubmed: 28331841
Dis Markers. 2018 Aug 14;2018:2514901
pubmed: 30186532
World J Gastroenterol. 2015 Oct 14;21(38):10790-810
pubmed: 26478671
J Biol Chem. 2010 Nov 5;285(45):34337-47
pubmed: 20801890
J Clin Virol. 2015 Sep;70:43-45
pubmed: 26305818
J Clin Microbiol. 2015 Mar;53(3):967-72
pubmed: 25520447